KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri.
Apoptosis
Bcl-2
Harakiri
Lanthanum
Multidrug resistance
Journal
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
ISSN: 1432-1327
Titre abrégé: J Biol Inorg Chem
Pays: Germany
ID NLM: 9616326
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
30
04
2021
accepted:
10
08
2021
pubmed:
8
10
2021
medline:
14
1
2022
entrez:
7
10
2021
Statut:
ppublish
Résumé
Despite high cure rates in pediatric patients with acute leukemia, development of resistance limits the efficacy of antileukemic therapy. Tris(1,10-phenanthroline)tris(thiocyanato-κN)lanthanum(III) (KP772) is an experimental antineoplastic agent to which multidrug-resistant cell models have shown hypersensitivity. Antiproliferative and apoptotic activities of KP772 were tested in leukemia, lymphoma and solid tumor cell lines as well as primary leukemia cells (isolated from the bone marrow of a child with acute myeloid leukemia (AML). The ability to overcome drug resistances was investigated in doxorubicin- and vincristine-resistant cell lines. Real-time PCR was used to gain insight into the mechanism of apoptosis induction. KP772 inhibited proliferation and induced apoptosis in various leukemia and lymphoma cell lines in a concentration-dependent manner (LC
Identifiants
pubmed: 34617137
doi: 10.1007/s00775-021-01900-9
pii: 10.1007/s00775-021-01900-9
pmc: PMC8557194
doi:
Substances chimiques
Antineoplastic Agents
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
897-907Informations de copyright
© 2021. The Author(s).
Références
J Immunol Methods. 1991 Jun 3;139(2):271-9
pubmed: 1710634
Cancer Discov. 2015 May;5(5):475-87
pubmed: 25895919
World J Gastroenterol. 2018 Aug 7;24(29):3222-3238
pubmed: 30090003
Acta Haematol. 1997;98(1):8-13
pubmed: 9210907
Curr Med Chem. 2008;15(20):1981-2039
pubmed: 18691054
Aging (Albany NY). 2016 Apr;8(4):603-19
pubmed: 27019364
Inorg Chem. 2010 May 3;49(9):4036-45
pubmed: 20380391
Pharmazie. 1994 Oct;49(10):759-61
pubmed: 7816902
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Int J Mol Sci. 2021 May 20;22(10):
pubmed: 34065345
Adv Exp Med Biol. 2019;1141:549-580
pubmed: 31571174
Vasa Suppl. 1991;33:140-1
pubmed: 1838623
Curr Cancer Drug Targets. 2009 Aug;9(5):595-607
pubmed: 19508176
Cell Death Discov. 2019 Feb 8;5:64
pubmed: 30774992
Cancer Gene Ther. 2006 Apr;13(4):420-7
pubmed: 16211087
Biochem Pharmacol. 2007 Jun 15;73(12):1873-86
pubmed: 17445775
Biochem Pharmacol. 2006 Feb 14;71(4):426-40
pubmed: 16343446
Bioorg Med Chem. 2007 Jan 1;15(1):533-40
pubmed: 17046270
Eur J Pharm Sci. 2000 Oct;11(4):265-83
pubmed: 11033070
J Inorg Biochem. 2006 Jan;100(1):36-43
pubmed: 16289294
Leukemia. 1995 Oct;9(10):1783-6
pubmed: 7564526
Leukemia. 2000 Sep;14(9):1606-13
pubmed: 10995007
Asian Pac J Cancer Prev. 2015;16(6):2129-44
pubmed: 25824729
Invest New Drugs. 2015 Aug;33(4):835-47
pubmed: 26091914
Blood. 2001 Mar 1;97(5):1378-87
pubmed: 11222383
Biochem J. 2000 Mar 15;346 Pt 3:777-83
pubmed: 10698706
Adv Exp Med Biol. 2019;1141:13-100
pubmed: 31571164
J Inorg Biochem. 2002 Apr 10;89(1-2):97-106
pubmed: 11931969